What Rezolute, Inc. does.

Rezolute, Inc. (“Rezolute”, the “Company”, “we” or “us”) is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (“HI”).

Our lead clinical asset, ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism.

Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. The antibody down modulates insulin receptor activity, thereby helping to restore glucose to a more normalized range in conditions associated with elevated insulin or insulin-like substances (e.g. IGF-2 variants). Ersodetug shows dose dependent pharmacokinetics with a half-life greater than 2 weeks, which has the potential for monthly dosing. Therefore, we believe that ersodetug is ideally suited as a potential therapy for conditions characterized by HI, and it is being developed to treat any form of HI. As ersodetug acts downstream from the cause of disease and source of HI (insulin or IGF-2 production), it has the potential to be universally effective at treating hypoglycemia related to HI, whether genetic or acquired.

Revenue and profit, by fiscal year.

More on RZLT.

• Rezolute, Inc. summary
• Rezolute, Inc. financial statements
• Rezolute, Inc. key metrics
• Rezolute, Inc. health scores and style box
• Rezolute, Inc. earnings
• Rezolute, Inc. dividends
• Rezolute, Inc. valuation
• Rezolute, Inc. ownership and insiders
• Rezolute, Inc. peers

Figures from Rezolute, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.